Related Experiment Video
Updated: Sep 19, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Impact of Patient Selection on Real-World Outcomes by Using the EMBRACE-II Treatment Protocol in Locally Advanced
Jacob Christian Lindegaard1, Christian Kirisits2, Maximilian Paul Schmid2
1Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Purpose:
External beam radiation therapy (EBRT), concomitant cisplatin, and magnetic resonance image guided adaptive brachytherapy performed according to the EMBRACE-II study protocol (IntErnational study on MRI-guided BRAchytherapy in locally advanced CErvical cancer) is considered state-of-the-art for the treatment of locally advanced cervical cancer. The aim of the present study was to evaluate the possibilities for realizing the planning aims and to assess the clinical outcome of using the EMBRACE-II treatment principles in real-world patients.
Methods And Materials:
The EMBRACE-II treatment protocol was implemented in 2015 at Aarhus University Hospital as standard for all patients. The present analysis comprises a consecutive cohort treated from 2015 to 2019.
Results:
In total 209 of 215 (97%) patients completed radiation therapy according to EMBRACE-II. Compared with 96 of 209 (46%) patients recruited in EMBRACE, major patient and disease related prognostic factors, were all significantly in disfavor for 113 of 209 (54%) patients treated according to EMBRACE-II, but not included in the trial. Nonetheless, the planning aims for EBRT and image guided adaptive brachytherapy were largely fulfilled in all patients. In contrast, the completion rate of 5 courses of concomitant cisplatin was reduced from 69% to 27% according to ± trial participation (P < .001) and was significantly influenced by age, comorbidity, performance status, and local tumor stage (P < .001). Overall 5-year local control was high (89%) and the rate of severe radiation-related side effects was low (7%). Advanced local tumor stage was a negative prognostic factor for loco-regional control, systemic control, and survival (P < .001), whereas concomitant cisplatin was important for EBRT-target control (P < .002).
Conclusions:
The dose-volume planning aims derived from EMBRACE-II for combining EBRT and brachytherapy are achievable in real-world patients while delivery of concomitant cisplatin is challenging. The use of carboplatin or increasing the dose of EBRT in patients unfit for concomitant cisplatin may be relevant for adjusting EMBRACE-II to the real world. In addition, wider indications for elective paraortic EBRT may be appropriate for patients with large primary tumors, irrespective of nodal status.
More Related Videos
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Nursing Interventions II: Selecting and Classifying the Nursing Interventions
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...